Key result
PAR-1 inhibition with vorapaxar reduces doxorubicin-induced cardiac injury and dysfunction in mice.
Why the study?
The role of protease-activated receptor 1 (PAR-1) in doxorubicin-induced cardiotoxicity was unclear.
Does PAR-1 inhibition or deficiency reduce doxorubicin-induced cardiotoxicity in mouse models?
Does PAR-1 inhibition or deficiency reduce doxorubicin-induced cardiotoxicity in mouse models?
PAR-1 activation contributes to doxorubicin-induced cardiotoxicity, suggesting PAR-1 inhibition could be a potential therapeutic approach for cancer patients receiving anthracyclines.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PAR-1 inhibition in anthracycline cardiotoxicity; leaves open translation to human patients.
Objective: The anti-cancer anthracycline drug Doxorubicin (Dox) causes cardiotoxicity. We investigated the role of protease-activated receptor 1 (PAR-1) in Dox-induced cardiotoxicity. Methods and results: In vitro experiments revealed that PAR-1 enhanced Dox-induced mitochondrial dysfunction, reactive oxygen species and cell death of cardiac myocytes and cardiac fibroblasts. The contribution of PAR-1 to Dox-induced cardiotoxicity was investigated by subjecting PAR-1−/− mice and PAR-1+/+ mice to acute and chronic exposure to Dox. Heart function was measured by echocardiography. PAR-1−/− mice exhibited significant less cardiac injury and dysfunction compared to PAR-1+/+ mice after acute and chronic Dox administration. PAR-1−/− mice had reduced levels of nitrotyrosine, apoptosis and inflammation in their heart compared to PAR-1+/+ mice. Furthermore, inhibition of PAR-1 in wild-type mice with vorapaxar significantly reduced the acute Dox-induced cardiotoxicity. Conclusion: Our results indicate that activation of PAR-1 contributes to Dox-induced cardiotoxicity. Inhibition of PAR-1 may be a new approach to reduce Dox-induced cardiotoxicity in cancer patients.
No takes yet. Share an insight, caveat, or question.
MacKman et al. (2020) studied Doxorubicin-induced cardiotoxicity. PAR-1 inhibition (genetic knockout or vorapaxar) vs. Wild-type (PAR-1+/+) mice was evaluated on Cardiac injury and dysfunction. Genetic deletion or pharmacological inhibition of PAR-1 with vorapaxar significantly reduced acute and chronic doxorubicin-induced cardiac injury and dysfunction in mice.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: